EXPERIENCE OF ENTEROSGEL APPLICATION IN THE CLINICAL UNIT OF CHILDHOOD ALLERGIC DISEASES, 2005
Lasitsya A.I. , Okhotnikova A.M., Revutskaya G.E., Gritsishina S.M., Tsigankova I.S.
RESULTS AND CONCLUSIONS
The comparative analysis of observation of two patient group (I group included the children received no Enterosgel (control) and II group included the children whose therapy involved this drug) showed that the improvement of the main clinical implications of disease (DRS) was diagnosed in the children received Enterosgel as a part of the complex therapy: in 75% of patients, the rash elements decreased in Day 3-4 after drug administration and Quicke's edema disappeared in Day 2-3 of treatment. The positive effect of the Enterosgel therapy on the dyspeptic syndrome was observed: stool was normalizaed and nausea was terminated. In 49% of patients, disappearance of the pain abdominal syndrome was noted. It should be said that, in children under 2 years, the improvement in the decrement of the main disease manifestations was less appreciable and more delayed. This is explained by the morphofunctional dismaturity of the gastrointestinal tract in children of this age (enzymatic and topical immunologic deficiency, late onset of the formation of intestinal microbiology). At the same time, in the control group children received no Enterosgel, the improvement of clinical signs of DRS was less considerable and diagnosed only in 22% of patients. Disappearance of the DRS syndromes, pain abdominal and dyspeptic syndromes was delayed up to 7-8 Day of the complex therapy.
Thus, based on the study performed, one can conclude that application of Enterosgel in the complex therapy of childhood allergic diseases is pathogenetically proved and reasonable.
EFFICIENCY OF ENTEROSGEL IN KIDNEY DISEASES IN CHILDREN LIVING IN THE THE CEMENT INDUSTRY REGION, 2015
Kudin M.V., Tsaregorodtsev A.D., Fedorov Y.N., Dlin V.V.
It has been established that the incidence of renal diseases in children in the regions of cement industry is very high, especially regarding dysmetabolic nephropathy, unlike the control region, which shows the significant role of environmental factors in the development of renal damage. The conducted studies of Kudin M.V. (2012)  have shown that in children and adults living in the area and having no renal diseases cadmium - toxic element, hazard class 1 - accumulates in kidney tissue, which justifies the use of enterosorbent Enterosgel in persons living in the region as a prophylactic purpose.
Enterosgel not only prevents accumulation of toxic substances into the body by their intestinal adsorption, but also contributes to the removal of heavy metals from the urinary system. Inclusion of Enterosgel in the therapy of children with renal diseases living in the region of cement industry leads to the increased urinary excretion of cadmium, chromium, antimony, and arsenic and improvement of urinary symptoms and, above all, reduction of proteinuria, reflecting improved reabsorption function of the epithelium of proximal tubules.
No undesirable effects have been registered in children receiving Enterosgel.
ENTEROSGEL IN THE COMPLEX THERAPY OF ALLERGIC DISEASES, 1998
Thus, Enterosgel is a highly-active safe drug, which is well-tolerated by patients. Administration of Enterosgel in the complex therapy of patients with allergic diseases allows reduction of the terms of hospital treatment of patients by 10-15%, decreasing the need for antihistamine drugs, glucocorticoids, and bronchial spasmolytics, and reducing the treatment expenses by 15-20%.
ENTEROSORPTION AS AN IMPORTANT METHOD OF TREATMENT OF ELIMINATING CHRONIC ENDOTOXIN AGGRESSION, 2007
Chernikhova E.A., Anikhovskaya I.A., Gataullin Yu.K., Zakirova D.Z., Ivanov V.B., Saveliev A.A., Yakovlev M.Yu.
Method of intestinal adsorption (enterosorption) can be used as a means of CEA elimination. Monotherapy with Enterosgel, the intestinal adsorbent of new generation, reduces the average LPS concentration in the general circulation by 56% and is capable to eliminate CEA in every fourth patient with chronic inflammatory diseases.
APPLICATION OF THE METHOD OF ENTEROSORPTION THERAPY BY SILICON ENTEROSORBENT ENTEROSGEL IN THE INTEGRATED TREATMENT OF ALLERGIC DISEASES, 2009
Goal of the research
Verification of clinical effectiveness and monitoring of the laboratoty values profile in patients with dermatic (atopic dermatitis, hibes) and respiratory (allergic asthma and allergic rhinitis) allergic symptoms in the period of main disease recrudescence. The influence of ENTEROSGEL taken was tested as a complementary influence in terms of the conventional basic treatment. For the purpose of making comparisons the same group of patients was monitored within the period prior to application of ENTEROSGEL.
ON ESTABLISHMENT OF LARGE-SCALE PRODUCTION AND HEALTHCARE IMPLEMENTATION OF NOVEL HIGHLY EFFECTIVE POLYORGANOSILOXANE-BASED ADSORBENT DRUGS WITH DETOXIFYING EFFECT, 1994
Bezlyuda N.P., Baranyuk A.P.
Novel intestinal and topical adsorbent drugs with detoxifying effect (studies were conducted in 1980-1990 by order of Main Military Clinical Hospital of the Ministry of Defense of Ukraine) were widely evaluated in military medical facilities. The Military Hospital of Kyiv (nowadays the Main Military Clinical Hospital of the Ministry of Defense of Ukraine) participated in the medical and biological evaluation of novel drugs from the beginning of their development (V.N. Fadeev, F.G. Novikov, N.P. Bezlyuda).